SCHEMBL5209029

SCHEMBL5209029

Cc1nc(-c2ccc(Cl)cc2)c(CCC(=O)N2CCS(=O)(=O)CC2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
GABRA5 P31644 1/20 0.42
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HPGD P15428 1/20 0.38
TACR1 P25103 1/20 0.37
MAPK1 P28482 2/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
SLC2A1 P11166 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5211815 0.87 POLB (0.47) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5215135 0.85 POLB (0.44) POLBMAPTLMNASMN1; SMN2TP53
SCHEMBL5209589 0.85 POLB (0.50) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5208176 0.83 POLB (0.42) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5211657 0.83 POLB (0.42) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5209904 0.83 POLB (0.40) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5210396 0.82 MEN1 (0.43) POLBMAPTLMNASMN1; SMN2TP53
SCHEMBL5210227 0.81 POLB (0.41) POLBMAPTLMNASMN1; SMN2TP53
SCHEMBL5215014 0.80 POLB (0.39) POLBGABRA5MAPTLMNASMN1; SMN2
SCHEMBL5212049 0.80 CNR1 (0.43) POLBTACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 POLB 3507/4885GABRA5 1852/4885MAPT 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.